Serum amyloid A (SAA) is a highly sensitive acute phase reactant that has been linked to inflammatory diseases, both infectious and non-infectious origin. SAA is an apolipoprotein that interacts with HDL, promotes the accumulation of leukocytes at the site of inflammation and the adhesion of platelets, and participates in the removal of damaged cell membranes. The acute phase SAAs (SAA1, SAA2) are transcriptionally regulated in hepatocytes by a variety of inflammatory cytokines, and they can transiently increase > 1000-fold. The combination of SAA, PCT, and CRP can improve the differential diagnosis of early bacterial and viral infections. Several studies indicated that SAA allows monitoring of disease activity in various inflammatory rheumatic diseases and autoinflammatory diseases, including SLE, amyloidosis, or rheumatoid arthritis. SAA can be also used to risk prediction of coronary heart disease, the prognosis of tumour patients, and observation of transplant rejection.
Enzyme Immunoassay for the quantitative determination of Serum amyloid A (SAA) in human serum, plasma, and other body fluids.
RESOURCES
- Levin M, Franklin EC, Frangione B, Pras M. The amino acid sequence of a major nonimmunoglobulin component of some amyloid fibrils. J Clin Invest. 1972;51:2773–6. https://doi.org/10.1172/ JCI107098. 3. Linke RP, Sipe JD, Pollock PS, Ignaczak TF, Glenner GG. Isolation of a low-molecular-weight serum component antigenically related to an amyloid fibril protein of unknown origin. Proc Natl Acad Sci U S A. 1975;72:1473–6. https://doi.org/10.1073/pnas.72. 4.1473.
- Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation. 2004;109:726–32. https://doi.org/10.1161/01.CIR.0000115516.54550.B1. 19. Kosuge M, Ebina T, Ishikawa T, Hibi K, Tsukahara K, Okuda J, et al. Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ J. 2007;71:186–90. https://doi.org/10.1253/circj. 71.186. 20. Deguchi H, Elias DJ, Navarro S, Espana F, Griffin JH. Elevated serum amyloid A is associated with venous thromboembolism. Thromb Haemost. 2013;109:358–9. https://doi.org/10.1160/ TH12-10-0722.
- Saiki O, Uda H. Ratio of serum amyloid A to C-reactive protein is constant in the same patients but differs greatly between patients with inflammatory diseases. Scand J Immunol. 2022 Feb;95(2):e13121. doi: 10.1111/sji.13121. Epub 2021 Nov 24. PMID: 34796986.
